Traditional Chinese medicine composition for improving ovarian function

By using a combination of traditional Chinese medicines such as ginseng and dodder seed, the systemic deficiencies of POI treatment are addressed, significantly improving ovarian function, reducing FSH and LH, increasing AMH and E2, alleviating related symptoms, and achieving safe and effective treatment results.

CN121987708APending Publication Date: 2026-05-08DONGZHIMEN HOSPITAL OF BEIJING UNIV OF CHINESE MEDICINE
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN202610191526.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2026-02-10
Publication Date
2026-05-08

AI Technical Summary

Technical Problem

Current technology has not fully clarified the etiology of POI, and traditional Chinese medicine combinations lack systematicity and effectiveness in treating ovarian insufficiency, especially in treating early-onset ovarian insufficiency (POI).

Method used

The formula uses ginseng and dodder seed as the principal herbs, combined with prepared rehmannia root, wolfberry, privet fruit, epimedium, morinda root, angelica root, and cornus fruit as the assistant herbs, cyperus rhizome and salvia root as adjuvant herbs, and prepared licorice root to harmonize the herbs. The resulting herbal composition is prepared into various dosage forms such as decoction, pills, and capsules through decoction, soaking, percolation, or ultrasonic extraction, and is used to improve ovarian function.

Benefits of technology

It significantly reduces FSH and LH levels, increases AMH and E2 levels, and improves symptoms such as hot flashes, sweating, insomnia, irritability, depression, fatigue, and discomfort during sexual activity. It is safe, effective, and has no side effects, and significantly improves ovarian function indicators.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN121987708A_ABST
    Figure CN121987708A_ABST
Patent Text Reader

Abstract

The invention provides a traditional Chinese medicine composition for improving ovarian function, which is prepared from the following raw material medicines in parts by weight: 1 to 5 parts of ginseng, 8 to 20 parts of semen cuscutae, 3 to 14 parts of radix angelicae sinensis, 8 to 20 parts of radix salviae miltiorrhizae, 4 to 14 parts of radix morindae officinalis, 6 to 15 parts of radix rehmanniae praeparata, 6 to 14 parts of fructus lycii, 6 to 18 parts of fructus ligustri lucidi, 3 to 13 parts of fructus corni, 3 to 13 parts of rhizoma cyperi, 3 to 12 parts of herba epimedii and 1 to 10 parts of liquorice root. All the medicines in the whole formula cooperate to tonify kidney and spleen, soothe liver and activate blood, harmonize yin and yang, regulate qi and blood, fill kidney essence and recover menstrual fluid gradually, so that the treatment purpose of improving the ovarian function is achieved.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention relates to the field of traditional Chinese medicine technology, specifically to a traditional Chinese medicine composition for improving ovarian function. Background Technology

[0002] Premature ovarian insufficiency (POI) refers to a decline in ovarian function in women before the age of 40, which in severe cases leads to ovarian failure, resulting in perimenopausal symptoms, infertility, and other manifestations. It seriously affects the patient's endocrine and reproductive functions, and its incidence is on the rise and affecting younger women. However, the etiology of POI is not fully understood, and its pathogenesis is still under investigation.

[0003] The clinical symptoms of POI (Potential Ovarian Inflammation) closely correspond to those of "scanty menstruation," "amenorrhea," "blood deficiency," "infertility," and "menopausal symptoms" in Traditional Chinese Medicine (TCM). These conditions have been discussed in ancient texts. For example, the functions and anatomical locations of the TCM concepts of "uterus" and "uterine vessels" are fundamentally similar to the modern medical understanding of the ovary. The *Huangdi Neijing* (Huangdi Neijing. [M]: Xi'an: Sanqin Press, 2018) states that the location of the uterine vessels "belongs to the heart and connects to the uterus," and proposes that the uterine vessels govern the menstrual rhythm, stating that "absence of menstruation indicates closure of the uterine vessels," directly linking to the core symptoms of POI. The concept of "premature aging" was also mentioned in the *Huangdi Neijing*: "If one understands the seven losses and eight benefits, then the two can be regulated; if one does not understand this, then premature aging will occur. At the age of forty, the yin energy is halved, and daily life declines," highlighting that the cause of premature aging is "the yin energy is halved," emphasizing the central role of yin essence deficiency in premature ovarian function decline. Modern Traditional Chinese Medicine (TCM) considers kidney deficiency to be the primary cause of premature ovarian insufficiency (POI), closely related to dysfunction of other organs such as the liver and spleen. Its pathogenesis is mainly characterized by "deficiency" and "stasis," leading to imbalances in Qi and blood, which in turn disrupts the "kidney-Tian Gui-Chong Ren-uterus" axis, ultimately resulting in POI symptoms such as decreased ovarian reserve and menstrual irregularities. Therefore, TCM, through syndrome differentiation and treatment, provides a unique and effective approach to the treatment of POI.

[0004] Combining relevant ancient texts and existing TCM theories, several TCM composition prescriptions have been proposed for symptoms such as ovarian insufficiency. Patent CN101919963B discloses a TCM composition for treating ovarian insufficiency and perimenopausal syndrome, comprising the following ingredients: Ligustrum lucidum, Morus alba fruit, Cistanche deserticola, Salvia miltiorrhiza, Achyranthes bidentata, Cyperus rotundus (processed), Paeonia lactiflora, Anemarrhena asphodeloides, and Lilium brownii. The core pathogenesis of this condition is liver stagnation, kidney deficiency, and blood stasis. The entire formula contains both Yin and Yang elements, focusing on tonifying the kidneys and promoting blood circulation, while also soothing the liver and regulating Qi, relieving depression and calming the mind, balancing Yin and Yang, and regulating the Chong and Ren meridians. Patent CN101850016B discloses a TCM composition for treating premature ovarian failure, comprising the following ingredients: Rehmannia glutinosa (processed), Cornus officinalis, Angelica sinensis, Paeonia lactiflora, Epimedium brevicornu, and Salvia miltiorrhiza. This formula is mainly used to treat premature ovarian failure of the liver and kidney yin deficiency type. In the formula, Rehmannia glutinosa and Cornus officinalis nourish yin and tonify the liver and kidney, and are the principal herbs; Angelica sinensis, Paeonia lactiflora, and Salvia miltiorrhiza tonify blood, promote blood circulation and regulate menstruation; Epimedium tonifies kidney yang; Salvia miltiorrhiza can also clear the heart and relieve irritability. Summary of the Invention

[0005] This invention provides a traditional Chinese medicine composition for improving ovarian function. Ginseng and Cuscuta are the principal herbs, protecting the essence of the prenatal and postnatal menstruation and laying the foundation for ovarian function repair. Rehmannia glutinosa, Lycium barbarum, Ligustrum lucidum, Epimedium brevicornu, Morinda officinalis, Angelica sinensis, and Cornus officinalis are the assistant herbs. These assistant herbs tonify Yin and Yang and regulate Qi and blood, synergistically enhancing the effects of the principal herbs, generating the source of menstrual flow, regulating Yin and Yang, Qi and blood, and strengthening the kidney-tonifying and essence-replenishing functions. Cyperus rotundus and Salvia miltiorrhiza are the adjuvant herbs, working together to soothe the liver, regulate Qi, invigorate blood, and nourish blood, assisting the principal and assistant herbs in regulating Qi and blood. Finally, Glycyrrhiza uralensis is used to harmonize all the herbs, achieving Yin-Yang balance, Qi and blood regulation, and replenishment of kidney essence, gradually restoring normal menstrual flow and thus achieving the therapeutic goal of improving ovarian function.

[0006] In a first aspect, the present invention provides a traditional Chinese medicine composition for improving ovarian function, comprising, by weight, the following raw materials: 1-5 parts ginseng, 8-20 parts dodder seed, 3-14 parts angelica root, 8-20 parts salvia miltiorrhiza, 4-14 parts morinda root, 6-15 parts prepared rehmannia root, 6-14 parts wolfberry, 6-18 parts privet fruit, 3-13 parts cornus fruit, 3-13 parts cyperus rhizome, 3-12 parts epimedium, and 1-10 parts licorice root.

[0007] Furthermore, the traditional Chinese medicine composition, by weight, comprises the following raw materials: ginseng 1-4 parts, dodder seed 9-17 parts, angelica 4-12 parts, salvia miltiorrhiza 9-17 parts, morinda root 5-13 parts, prepared rehmannia root 8-13 parts, wolfberry 7-13 parts, privet fruit 7-16 parts, cornus officinalis 4-12 parts, cyperus rhizome 4-12 parts, epimedium 5-11 parts, and licorice root 1-8 parts.

[0008] In a specific embodiment of the present invention, the traditional Chinese medicine composition comprises, by weight, the following raw materials: 3 parts ginseng, 12 parts dodder seed, 6 parts angelica, 12 parts salvia miltiorrhiza, 9 parts morinda officinalis, 9 parts prepared rehmannia root, 9 parts wolfberry, 9 parts privet fruit, 6 parts cornus officinalis, 6 parts cyperus rotundus, 9 parts epimedium and 6 parts licorice.

[0009] In a specific embodiment of the present invention, the traditional Chinese medicine composition comprises, by weight, the following raw materials: 3 parts ginseng, 15 parts dodder seed, 10 parts angelica, 15 parts salvia miltiorrhiza, 12 parts morinda officinalis, 12 parts prepared rehmannia root, 12 parts wolfberry, 15 parts privet fruit, 10 parts cornus officinalis, 10 parts cyperus rotundus, 9 parts epimedium and 6 parts licorice.

[0010] In a specific embodiment of the present invention, the traditional Chinese medicine composition comprises, by weight, the following raw materials: 2 parts ginseng, 10 parts dodder seed, 8 parts angelica, 10 parts salvia miltiorrhiza, 6 parts morinda officinalis, 9 parts prepared rehmannia root, 9 parts wolfberry, 9 parts privet fruit, 6 parts cornus officinalis, 6 parts cyperus rotundus, 6 parts epimedium and 2 parts licorice.

[0011] Specifically, Morinda officinalis is selected from processed Morinda officinalis, which may include, but is not limited to, processed Morinda officinalis, salted Morinda officinalis, or Morinda officinalis meat, with processed Morinda officinalis being the preferred choice.

[0012] Specifically, privet fruit is called wine-processed privet fruit, cornelian cherry is called wine-processed cornelian cherry, and licorice is called roasted licorice.

[0013] The second aspect of the present invention provides a method for preparing a traditional Chinese medicine composition, wherein ginseng, dodder seed, angelica, salvia miltiorrhiza, morinda officinalis, rehmannia glutinosa, wolfberry, privet fruit, cornus officinalis, cyperus rotundus, epimedium and licorice are weighed according to selected mass proportions, mixed and extracted to obtain the composition.

[0014] Specifically, the extraction method includes one or more of the following: decoction extraction, maceration extraction, percolation extraction, reflux extraction, and ultrasonic extraction, especially decoction extraction.

[0015] Specifically, the extraction is performed at least once, preferably 1-5 times, and more preferably 1-3 times.

[0016] Specifically, the extraction time is at least 20 min, preferably 20-120 min (e.g., 20 min, 30 min, 40 min, 50 min, 60 min, 70 min, 80 min, 90 min, 100 min, 110 min or 120 min, etc.), and more preferably 20-90 min.

[0017] Specifically, the extraction agent added during the extraction process is 2-15 times its mass, preferably 2-8 times its mass.

[0018] Specifically, the extractant is water.

[0019] In a specific embodiment of the present invention, ginseng, dodder seed, angelica, salvia miltiorrhiza, prepared morinda root, prepared rehmannia root, wolfberry, wine-processed privet fruit, wine-processed cornus fruit, cyperus rhizome, epimedium, and prepared licorice root are weighed according to the selected mass proportions, soaked in 2-8 times the mass of water for 20-40 minutes, decocted 1-3 times, each time for 20-90 minutes, and then the decoction is filtered, combined and concentrated to obtain the final product.

[0020] A third aspect of the present invention provides a traditional Chinese medicine preparation for improving ovarian function, wherein the active ingredients include the traditional Chinese medicine composition described in the first aspect or the traditional Chinese medicine composition obtained by the preparation method described in the second aspect.

[0021] Specifically, the traditional Chinese medicine preparations include decoctions, pills (water pills, honey pills, concentrated pills), capsules, granules, tablets, ointments, drop pills, plasters, or lotions, preferably decoctions.

[0022] Specifically, the traditional Chinese medicine preparation also includes pharmaceutically acceptable excipients selected from one or more of the following: solubilizers, cosolvents, emulsifiers, colorants, binders, disintegrants, fillers, lubricants, wetting agents, osmotic pressure regulators, stabilizers, flow aids, flavoring agents, preservatives, suspending agents, coating materials, fragrances, anti-adhesives, integrators, penetration enhancers, pH adjusters, buffers, plasticizers, surfactants, thickeners, inclusion agents, humectants, absorbents, diluents, flocculants and anti-flocculators, filter aids, release inhibitors, polymeric framework materials, and film-forming materials.

[0023] A fourth aspect of the present invention provides a method for preparing a traditional Chinese medicine preparation as described in the third aspect, the method comprising the following steps: 1) Extraction of Chinese herbal composition: Weigh out ginseng, dodder seed, angelica, salvia miltiorrhiza, morinda officinalis, rehmannia glutinosa, wolfberry, privet fruit, cornus officinalis, cyperus rotundus, epimedium and licorice according to the selected mass proportions, mix and extract, filter and concentrate to obtain the Chinese herbal composition extract. 2) Add excipients to the extract of the traditional Chinese medicine composition to prepare a dosage form that is acceptable in clinical practice.

[0024] In a fifth aspect, the present invention provides the use of the traditional Chinese medicine composition as described in the first aspect, or the traditional Chinese medicine composition obtained by the preparation method described in the second aspect, or the traditional Chinese medicine preparation as described in the third aspect, or the traditional Chinese medicine preparation obtained by the preparation method described in the fourth aspect, in the preparation of a medicament for improving ovarian function.

[0025] Specifically, diseases that cause decreased ovarian function include premature ovarian insufficiency, reduced ovarian reserve, and ovarian hyporesponsiveness.

[0026] Furthermore, diseases that cause decreased ovarian function include premature ovarian insufficiency (POI, including premature ovarian failure POF), decreased ovarian reserve, ovarian hyporesponsiveness, perimenopausal syndrome, and secondary ovarian injury.

[0027] Furthermore, the main TCM syndrome type corresponding to decreased ovarian function is kidney deficiency and liver stagnation.

[0028] In a sixth aspect, the present invention provides a medicament for improving ovarian function.

[0029] The medicine includes the traditional Chinese medicine composition as described in the first aspect or the traditional Chinese medicine composition obtained by the preparation method described in the second aspect; or Traditional Chinese medicine preparations as described in the third aspect or traditional Chinese medicine preparations obtained by the preparation method described in the fourth aspect.

[0030] Specifically, the drug also includes pharmaceutically acceptable excipients.

[0031] In a seventh aspect, the present invention provides a method for improving ovarian function.

[0032] Specifically, the method includes administering a traditional Chinese medicine composition or preparation to a subject in need.

[0033] Specifically, the administration method includes gastrointestinal administration (e.g., oral administration).

[0034] In the traditional Chinese medicine composition of the present invention, ginseng and dodder seed are the principal herbs; prepared rehmannia root, wolfberry, privet fruit, epimedium, morinda root, angelica root, and cornus fruit are the assistant herbs; cyperus rhizome and salvia root are the adjuvant herbs; and prepared licorice root is the guiding herb.

[0035] Among them, ginseng and dodder seed are the principal herbs. Ginseng is sweet and slightly bitter, warm, and enters the spleen and lung meridians. It strengthens the spleen and replenishes qi, and replenishes the deficiency of spleen and kidney qi. Dodder seed is pungent and sweet, neutral, and enters the liver, kidney, and spleen meridians. Together, they nourish kidney yin and kidney yang, and nourish kidney qi and kidney essence. The two herbs complement each other and work together to achieve the core effect of protecting the essence of the two days of life and laying the foundation for the repair of ovarian function. The formula uses Rehmannia glutinosa, Lycium barbarum, Ligustrum lucidum, Epimedium brevicornu, Morinda officinalis, Angelica sinensis, and Cornus officinalis as assistant herbs. Rehmannia glutinosa, Lycium barbarum, Ligustrum lucidum, and Cornus officinalis replenish true Yin and harmonize the Yin and Yang. Epimedium brevicornu and Morinda officinalis warm the kidneys and assist Yang, and their pungent nature can moisten Yin essence. Angelica sinensis nourishes blood, invigorates blood circulation, and harmonizes the Chong and Ren meridians. The assistant herbs in the entire formula replenish Yin and Yang and regulate Qi and blood. It not only takes the meaning of Yang being assisted by Yin so that its source is inexhaustible, but also Yin being elevated by Yang so that its generation is endless. It also works synergistically with the principal herbs to enhance the effect, replenish the source of menstrual blood, regulate Yin and Yang Qi and blood, and strengthen the function of tonifying the kidneys and replenishing essence. Cyperus rotundus and Salvia miltiorrhiza are used as adjuvants. Cyperus rotundus is light and refreshing, which can soothe the liver and relieve depression, so that the liver qi can be regulated and the qi and blood can flow smoothly. Salvia miltiorrhiza has the same effect as Siwu Decoction, which can invigorate blood, nourish blood, remove blood stasis and regulate menstruation, and improve the local microcirculation of the ovary. The two complement each other and work together to soothe the liver and regulate qi, invigorate blood and nourish blood, and help the principal and assistant drugs to regulate qi and blood. Finally, roasted licorice root is used as the guiding herb. Its sweet and warm properties benefit qi, harmonize the effects of other herbs, and also invigorate qi and strengthen the spleen.

[0036] The combined effects of all the herbs in this formula can benefit the kidneys and spleen, soothe the liver and promote blood circulation, harmonize yin and yang, regulate qi and blood, replenish kidney essence, and gradually restore menstruation to normal, thereby achieving the therapeutic goal of improving ovarian function.

[0037] The beneficial effects of this invention are: The traditional Chinese medicine composition provided by this invention has been experimentally proven to significantly reduce FSH and LH levels while increasing AMH and E2 levels. It significantly improves common clinical symptoms such as hot flashes, sweating, insomnia, irritability, depression, fatigue, and sexual discomfort. Furthermore, no adverse events were observed during clinical treatment. Animal experiments also showed improvements in FSH levels and the number of mature follicles, indicators of ovarian function. These findings indicate that the traditional Chinese medicine composition is safe, effective, and without side effects, and can effectively improve ovarian function. Attached Figure Description

[0038] The embodiments of the present invention will now be described in detail with reference to the accompanying drawings, wherein: Figure 1 The changes in body weight of rats in each group are shown in Figure A, where A is the curve of body weight change of rats in each group over time during the drug administration period, and B is the comparison of body weight of rats in each group at the beginning (D1) and the end (D29) of the experiment.

[0039] Figure 2 : Graph showing the changes in ovarian index in rats of each group.

[0040] Figure 3 Typical images of vaginal smears from rats at different estrous cycles.

[0041] Figure 4 : Graph showing the changes in rats in different estrous cycles.

[0042] Figure 5 Image showing HE staining results of rat ovaries in each group. Black arrows indicate mature follicles, red arrows indicate atretic follicles, and green arrows indicate secondary follicles.

[0043] Figure 6 : Graph showing the changes in the number of primordial follicles (A), primary follicles (B), secondary follicles (C), mature follicles (D), atretic follicles (E), and corpus luteum (F) in each group of rats.

[0044] Figure 7 : Calculation results of follicular atresia rate in each group of rats.

[0045] Note: ### represents P<0.001 compared to the Control group, ## represents P<0.01 compared to the Control group; *** represents P<0.001 compared to the Model group, ** represents P<0.01 compared to the Model group, and * represents P<0.05 compared to the Model group. Detailed Implementation

[0046] The technical solutions of the embodiments of the present invention will be clearly and completely described below with reference to the accompanying drawings. Obviously, the described embodiments are only some embodiments of the present invention, and not all embodiments. Based on the embodiments of the present invention, all other embodiments obtained by those skilled in the art without creative effort are within the scope of protection of the present invention.

[0047] As used herein, the term "parts by weight" can be any fixed weight expressed in milligrams, grams, or kilograms (e.g., 1 mg, 1 g, 2 g, 5 g, or 1 kg). For example, a composition consisting of 1 part by weight of component a and 9 parts by weight of component b can be a composition consisting of 1 g of component a + 9 g of component b, or 10 g of component a + 90 g of component b, etc.

[0048] The subjects in this invention are preferably mammals. The term "mammal" primarily refers to warm-blooded vertebrate mammals, including but not limited to: cats, dogs, rabbits, bears, foxes, wolves, monkeys, deer, mice (such as rats and mice), pigs, cattle, sheep, horses, and humans, with primates being preferred, and humans being more preferred. Taking the subject of the traditional Chinese medicine composition as an example, it refers to an animal receiving the traditional Chinese medicine composition for the treatment, prevention, reduction, and / or relief of diseases, symptoms, or conditions.

[0049] The patient in this invention refers to an animal, preferably a mammal, and more preferably a human.

[0050] The raw materials used were provided by the pharmacy of Dongzhimen Hospital of Beijing University of Chinese Medicine, and all raw materials passed quality inspection.

[0051] In the extraction process, the mass multiple refers to the number of milliliters of water added per gram of raw material.

[0052] According to the "human and animal body surface area calculation method", the drug dosage is the equivalent dosage for humans and animals calculated based on body surface area.

[0053] Example 1 Composition: Ginseng 3g, Cuscuta chinensis 15g, Angelica sinensis 10g, Salvia miltiorrhiza 15g, Morinda officinalis (processed) 12g, Rehmannia glutinosa (processed) 12g, Lycium barbarum 12g, Ligustrum lucidum (processed with wine) 15g, Cornus officinalis (processed with wine) 10g, Cyperus rotundus 10g, Epimedium brevicornu 9g, Glycyrrhiza uralensis (processed with wine) 6g.

[0054] Preparation: Take ginseng, dodder seed, angelica, salvia miltiorrhiza, prepared morinda root, prepared rehmannia root, wolfberry, wine-processed privet fruit, wine-processed cornus fruit, cyperus rhizome, epimedium, and prepared licorice root. Soak in 8 times their weight of water for 30 minutes, then decoct. After the first boil, decoct for 1.5 hours; for the second boil, add 3 times their weight of water, boil, and decoct for 1 hour; for the third boil, add 3 times their weight of water, boil, and decoct for 0.5 hours. Filter, combine, and concentrate the three decoctions to 125 ml to obtain the decoction.

[0055] Example 2 Composition: Ginseng 3g, Cuscuta chinensis 12g, Angelica sinensis 6g, Salvia miltiorrhiza 12g, Morinda officinalis (processed) 9g, Rehmannia glutinosa (processed) 9g, Lycium barbarum 9g, Ligustrum lucidum (processed with wine) 9g, Cornus officinalis (processed with wine) 6g, Cyperus rotundus 6g, Epimedium brevicornu 9g, Glycyrrhiza uralensis (processed with wine) 6g.

[0056] Preparation: Take ginseng, dodder seed, angelica, salvia miltiorrhiza, prepared morinda root, prepared rehmannia root, wolfberry, wine-processed privet fruit, wine-processed cornus fruit, cyperus rhizome, epimedium, and prepared licorice root. Soak in 8 times their weight of water for 30 minutes, then decoct. After the first boil, decoct for 1.5 hours; for the second boil, add 3 times their weight of water, boil, and decoct for 1 hour; for the third boil, add 3 times their weight of water, boil, and decoct for 0.5 hours. Filter, combine, and mix the three decoctions, concentrate to a thick extract, add pharmaceutical excipients, vacuum dry, pulverize into granules, and fill into capsules to obtain capsules.

[0057] Example 3 Composition: Ginseng 2g, Cuscuta chinensis 10g, Angelica sinensis 8g, Salvia miltiorrhiza 10g, Morinda officinalis 6g, Rehmannia glutinosa 9g, Lycium barbarum 9g, Ligustrum lucidum 9g, Cornus officinalis 6g, Cyperus rotundus 6g, Epimedium brevicornu 6g, Glycyrrhiza uralensis 2g.

[0058] Preparation: Take ginseng, dodder seed, angelica, salvia miltiorrhiza, prepared morinda root, prepared rehmannia root, wolfberry, wine-processed privet fruit, wine-processed cornus fruit, cyperus rhizome, epimedium, and prepared licorice root. Soak in 8 times their weight of water for 30 minutes, then decoct. After the first boil, decoct for 1.5 hours; for the second boil, add 3 times their weight of water, boil, and decoct for 1 hour; for the third boil, add 3 times their weight of water, boil, and decoct for 0.5 hours. Filter, combine, and concentrate the three decoctions to a thick extract. Add appropriate pharmaceutical excipients, granulate, dry, granulate, and package into granules.

[0059] Example 4: Clinical efficacy trial 1. Source of cases Forty-eight patients with kidney deficiency and liver stagnation type POI who visited the Department of Gynecology at Dongzhimen Hospital of Beijing University of Chinese Medicine between July 2023 and July 2024 and met the inclusion and exclusion criteria were collected (ethics approval number: 2023DZMEC-290).

[0060] 2. Diagnostic criteria 2.1 Western Medicine Diagnostic Criteria for POI Referring to the "Guidelines for the Integrated Traditional Chinese and Western Medicine Diagnosis and Treatment of Premature Ovarian Insufficiency" (Guidelines for the Integrated Traditional Chinese and Western Medicine Diagnosis and Treatment of Premature Ovarian Insufficiency [J]. Journal of Traditional Chinese Medicine, 2022, 63(12): 1193-1198.), the ESHRE Guideline: Management of women with premature ovarian insufficiency (Eshre guideline: Management of women with premature ovarian insufficiency [J]. Human Reproduction, 2016, 31(5): 926-937.), and the relevant diagnostic criteria in the 9th edition of Obstetrics and Gynecology (Obstetrics and Gynecology 9th Edition. [M]: Beijing: People's Medical Publishing House, 2018.), the Western medicine diagnostic criteria for POI are proposed as follows: (1) Age <40 years old, with a history of regular menstruation, experiencing oligomenorrhea or amenorrhea for more than 4 months.

[0061] (2) At least two serum baseline FSH levels > 25 U / L (interval > 4 weeks).

[0062] If both conditions (1) and (2) are met, POI can be diagnosed.

[0063] 2.2 Diagnostic Criteria for Traditional Chinese Medicine Syndromes Referring to relevant chapters on "Amenorrhea, Delayed Menstruation, Oligomenorrhea, Premenopausal and Menopausal Symptoms, and Infertility" in *Traditional Chinese Medicine Diagnostics* (2nd Edition, Beijing: Science Press, 2022) and *Traditional Chinese Medicine Gynecology* (4th Edition, Beijing: People's Medical Publishing House, 2021), the following TCM syndrome diagnostic criteria for POI of the kidney deficiency and liver stagnation type are proposed: (1) Main symptoms: ① menstrual cycle is early, menstrual cycle is late, amenorrhea, ② scanty menstruation.

[0064] (2) Secondary symptoms: ① hot flashes and sweating; ② dizziness and tinnitus; ③ significantly increased frequency of urination; ④ soreness and weakness of the waist and knees; ⑤ decreased libido; ⑥ chest tightness and rib distension; ⑦ irritability and anger; ⑧ depression; ⑨ breast tenderness during menstruation; ⑩ insomnia and dreaminess.

[0065] (3) Tongue and pulse: The tongue is pale and dark, with a white coating, and the pulse is deep, weak, or thin and wiry at the cun position.

[0066] The above primary symptoms are essential, and at least two secondary symptoms must be present, including at least one of ① to ⑤ and at least one of ⑥ to ⑩. Combined with the tongue and pulse diagnosis, the condition can be identified as kidney deficiency and liver stagnation syndrome.

[0067] 2.3 Inclusion Criteria (1) Patients diagnosed by Western medicine as having early-onset ovarian insufficiency.

[0068] (2) Patients diagnosed with kidney deficiency and liver stagnation syndrome by traditional Chinese medicine.

[0069] (3) Patients aged 18 to 39 years (including patients aged 18 and 39).

[0070] (4) Patients who voluntarily participate in this study, sign an informed consent form, and agree to the treatment plan.

[0071] Patients must meet all four of the above criteria to be included in the POI patient group of this study.

[0072] 2.4 Exclusion Criteria (1) Congenital gonadal developmental abnormalities.

[0073] (2) Patients with POI caused by radiotherapy, chemotherapy, unilateral or bilateral ovarian surgery and related procedures.

[0074] (3) Those who have used sex hormones or immunosuppressants within the past month, which may affect the assessment of efficacy or safety.

[0075] (4) Comorbid malignant tumors, cardiovascular and cerebrovascular diseases, liver and kidney diseases, and mental disorders.

[0076] (5) Patients who are breastfeeding.

[0077] (6) Patients who are allergic to the drugs used in this study or have a history of allergy to traditional Chinese medicine.

[0078] If any of the above six criteria are met, the study will exclude the candidate from inclusion in this study.

[0079] 2.5 Shedding Criteria All cases that have signed informed consent and met the inclusion criteria but have not completed the full course of treatment include: patients who were unable to complete treatment for any reason, those who withdrew voluntarily, and those who were lost to follow-up.

[0080] 2.6 Termination Criteria (1) If pregnancy occurs during treatment, treatment should be stopped immediately.

[0081] (2) If serious complications or other serious diseases occur during the treatment process, the treatment shall be stopped immediately and recorded.

[0082] 2.7 Exclusion Criteria (1) Those who fail to take medication as prescribed or do not comply with the treatment plan.

[0083] (2) Subjects who experience serious adverse reactions, complications, or special physiological changes during treatment that make it unsuitable to continue the trial.

[0084] (3) Automatically exit the researcher.

[0085] (4) Other diseases that affect the treatment of this study occurred during the treatment period.

[0086] 3. Treatment Plan The patient took 125ml of the decoction of the Chinese herbal composition prepared in Example 1, half an hour after meals, twice a day, one packet each time, for three consecutive months.

[0087] 4. Observation and evaluation of therapeutic effects (1) Main therapeutic indicators Between 8 and 10 a.m., blood was drawn from the antecubital vein of patients in an empty stomach, and serum FSH levels were measured in amenorrhea patients before medication and on days 2 to 4 of menstruation 3 months after medication.

[0088] (2) Secondary efficacy indicators Between 8 and 10 a.m., blood was drawn from the antecubital vein of patients in an empty stomach. Serum AMH, E2, and LH levels were measured in amenorrhea patients before medication and on days 2 to 4 of menstruation 3 months after medication.

[0089] (3) Modified Kupperman scale scoring.

[0090] The Kupperman scale (Cao Zeyi. Chinese Obstetrics and Gynecology. Beijing: People's Medical Publishing House, 2004) was modified, and the scores were measured at two time points: before and after the patients started medication.

[0091] 5. Statistical Methods General data were analyzed using descriptive methods, and count data were described using proportions. Quantitative data underwent a normality test; if they conformed to a normal distribution, the mean ± standard deviation was used as the statistical unit. ) indicates that a distribution not satisfying a normal distribution is defined by the median and the upper and lower quartiles M(P). 25 ,P 75 )express.

[0092] Data before and after treatment, and within each group, were compared. Paired t-tests were used for data that conformed to a normal distribution; otherwise, Wilcoxon tests were used. A p-value < 0.05 was considered statistically significant.

[0093] 6. Results Analysis This study included 48 patients with point of interest (POI) and 24 matched healthy female controls. The age, height, weight, and BMI of both groups did not conform to a normal distribution, and Wilcoxon test was used for analysis.

[0094] Table 1 shows that there were no significant differences in age, height, weight, and BMI between the enrolled POI patients and healthy female controls (P>0.05), indicating that the baselines of the two groups were basically the same and comparable.

[0095] Table 1. Comparison of age and BMI between POI and healthy control group 6.1 Primary therapeutic indicators During the study, 3 out of 48 POI patients became pregnant, and the outcome was clinically cured. The trial protocol was discontinued, and no other indicators were evaluated after treatment. The remaining 45 patients underwent an overall evaluation of the efficacy results.

[0096] According to the results in Table 2, the serum FSH level was significantly reduced after treatment with the traditional Chinese medicine decoction (P<0.001).

[0097] Table 2 Comparison of major efficacy indicators before and after POI treatment Note: Compared with before POI treatment ▲▲▲ P<0.001.

[0098] 6.2 Secondary efficacy indicators The changes in serum AMH, LH, E2, and FSH / LH levels were analyzed, and the results are shown in Table 3. It was found that there were significant differences in serum AMH, LH, and FSH / LH levels between the healthy control group and before POI treatment (P<0.001), and there was also a difference in E2 level (P<0.01). After treatment with the traditional Chinese medicine decoction of the present invention, compared with before treatment, LH level was significantly improved (P<0.001), and AMH level was improved (P<0.05).

[0099] Table 3 Comparison of serum secondary efficacy indicators before POI treatment, healthy control group, and after POI treatment. Note: Compared with the healthy control group △△△ P<0.001, △△ P<0.01; compared with before POI treatment, ▲▲▲ P<0.001, ▲ P<0.05.

[0100] 6.3 Modified Kupperman Scale Scoring The modified Kupperman scale was used to evaluate perimenopausal symptoms in POI patients before and after treatment. The numerical distribution of the items did not conform to normality, so the Wilcoxon test was used.

[0101] According to the results in Table 4, it was found that after treatment with the decoction of the traditional Chinese medicine composition of the present invention, the total score of POI patients was significantly improved (P<0.001). Specifically analyzing each item, it can be seen that after treatment, symptoms such as hot flashes and sweating, insomnia, irritability, depression, fatigue, and sexual discomfort were significantly improved (P<0.001), paresthesia and muscle and joint pain were improved (P<0.01), and headache and palpitations were significantly improved (P<0.05); while symptoms such as dizziness, skin crawling sensation, and urinary irritation were not significantly improved (P>0.05).

[0102] Table 4 Perimenopausal symptoms before and after POI treatment Note: Compared with before POI treatment, △△△ P<0.001, △△ P<0.01,△ P<0.05.

[0103] 6.4 Safety observation During the process of this study, no adverse events occurred in the patients during the treatment period. The vital signs were stable before and after treatment, and the results of blood and urine routine tests and liver and kidney function tests were normal.

[0104] Example 5 Animal experiment 1.1 Experimental animals and feeding conditions SPF-grade SD rats, female, 6-8 weeks old, weighing 180±20 g, were purchased from Beijing Vital River Laboratory Animal Technology Co., Ltd., and the animal production license number was: SCXK (Beijing) 2021-0006.

[0105] The experimental rats were housed in the Experimental Animal Center of the Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences. The lighting conditions were set as a cycle of 12 hours of light and 12 hours of darkness, the temperature range was controlled at 22±2°C, the relative humidity was controlled at 50±10%, and the animals were distributed ≤5 per cage. They could drink water freely and eat standard feed freely.

[0106] After 3 days of adaptive feeding, animal experiments were carried out. During the adaptation period, the rats were monitored for health to ensure no obvious abnormal behaviors or signs of diseases. (Ethical review number: 2023B269).

[0107] 1.2 Experimental drugs The concentrated solution of the traditional Chinese medicine complex was a decoction prepared by the preparation method of Example 1.

[0108] Tripterygium glycosides tablets: produced by Yuanda Pharmaceutical Huangshi Feiyun Pharmaceutical Co., Ltd., 10 mg×50 tablets / bottle, national drug approval number Z42021212.

[0109] Estradiol Valerate Tablets (Progynova): Manufactured by Delpham Lille SAS, 1 mg × 21 tablets / box, Imported Drug Registration Standard JX20100066, Approval Number H20160679.

[0110] 1.3 Experimental Instruments and Reagents The experimental instruments and reagents used in the examples are shown in Table 5-6.

[0111] Table 5 Main Experimental Instruments Table 6 Main Experimental Drugs and Reagents 2.1 Drug Preparation Preparation of Chinese herbal compound aqueous suspension: According to the preparation method in Example 1, a concentrated solution of Chinese herbal compound was obtained. Referring to the calculation method of human and animal body surface area, low, medium and high dose Chinese herbal compound aqueous suspensions were prepared at a clinical dose of 500 mL / (50 kg·d) (equivalent to 0.5 times, 1.0 times and 2.0 times the clinical equivalent dose, respectively).

[0112] After grinding estradiol valerate, double-distilled water was added to prepare an aqueous suspension with a concentration of 8 mg / L, which was then stored in a low-temperature freezer at -20°C to 4°C.

[0113] After grinding all Tripterygium wilfordii polyglycoside tablets, double-distilled water was added to prepare an aqueous suspension with a concentration of 5 mg / mL, which was then stored in a low-temperature refrigerator at -20℃ to 4℃.

[0114] 2.2 Establishment of animal models After 3 days of acclimatization, vaginal exfoliative cytology was performed daily, and a total of 40 healthy rats with regular estrous cycles were selected to enter the experiment.

[0115] Following the classic modeling method (Huangdi Neijing. [M]: Xi'an: Sanqin Publishing House, 2018.), except for the blank group, rats were constructed using Tripterygium wilfordii polyglycoside tablets 50 mg / (kg·d) by gavage once every morning for 14 consecutive days. From the 15th day after modeling, vaginal exfoliative cytology was observed daily, and the appearance of estrous cycle disorder indicated successful modeling.

[0116] 2.3 Experimental grouping and drug administration Grouping: Rats that did not develop the model were assigned to the blank control group (Control). Rats that successfully developed the model were randomly divided into the model group (Model), the positive control group (Progynova), and the low, medium, and high dose groups of the compound Chinese medicine suspension (JJGS-L, JJGS-M, and JJGS-H), with 6-8 rats in each group.

[0117] Administration: Based on the equivalent dose ratio table calculated according to the body surface area of ​​humans and animals, aqueous suspensions of each drug were prepared by adding double-distilled water. The blank control group was given an equal volume of double-distilled water. The specific drug concentrations are shown in the table below. The drugs were administered by gavage once daily in the afternoon for four consecutive weeks.

[0118] Table 7 Animal Experiment Grouping and Intervention Measures 2.4 General Observation The first day of modeling was recorded as D1. The rats were weighed every 3-5 days in the morning and the weight was recorded, for a total of 7 weight records. The rats' diet, fur, and activity were observed daily, and any abnormalities were recorded promptly.

[0119] 2.5 Estrous Cycle Detection Starting from day 15, vaginal exfoliative cytology was performed daily to assess changes in the estrous cycle. A 0.1% crystal violet solution was prepared using double-distilled water. A moistened cotton swab was gently rotated 0.5 cm into the rat's vagina to collect exfoliated cells, which were then smeared onto a glass slide. After air-drying, anhydrous ethanol was added for fixation for 10 min, followed by staining with 0.1% crystal violet solution for 1 min, washing with running water for 1 min, and then air-drying before mounting and storage. Cell morphology was observed under a regular optical microscope to differentiate between proestrus, estrus, metestrus, and diaestrus.

[0120] 2.6 Sample Collection After the last gavage, rats in each group were fasted for 12 hours at night. On the morning of D29, their body weight was measured, and they were anesthetized by intraperitoneal injection of 3% pentobarbital while in a quiet state. Blood was collected from the abdominal aorta, allowed to stand at room temperature for 1 hour, and then centrifuged at 3000 rpm for 15 minutes. The supernatant was collected, aliquoted into EP tubes, and stored at -80℃.

[0121] Bilateral ovarian and uterine tissue specimens were dissected from rats via laparotomy. The right ovary was fixed in 4% paraformaldehyde solution for 24 hours (6 rats per group), and the remaining ovarian tissue was temporarily stored in liquid nitrogen. After the collection, all specimens were transferred to a -80℃ freezer for cryopreservation for subsequent testing.

[0122] 2.7 Ovarian Index Calculation After removing tissue from both ovaries, they were weighed, and the ovarian index was calculated based on the last body weight. The calculation formula is as follows: Ovarian index (%) = wet weight of both ovaries / last body weight.

[0123] 2.8 Serum FSH, LH, E2, and AMH Detection Strictly follow the instructions for the kit and use the ELISA method to detect FSH, LH, E2, and AMH levels.

[0124] 2.9 HE staining of ovarian tissue and counting of follicles at each stage HE staining was used to observe and count follicles at each stage. Ovarian tissue sections were prepared and stained with hematoxylin and eosin, and the histological morphology and changes of the ovaries were observed under a microscope. The number of primordial follicles, primary follicles, secondary follicles, mature follicles, atretic follicles, and corpora lutea in each group of ovarian tissue sections were counted, and the total follicular atresia rate was calculated. The specific steps are as follows: (1) Ovarian tissue was fixed with 4% paraformaldehyde solution for 24 h at room temperature.

[0125] (2) Dehydration and transparent paraffin infusion: In a tissue dehydration machine, the ovarian tissue was successively immersed in 95% ethanol for 1 h, anhydrous ethanol for 2 h, xylene I for 10 min, xylene II for 10 min, paraffin I for 1 h, paraffin II for 2 h, and paraffin III for 3 h.

[0126] (3) Cut 5 μm thick tissue sections from the tissue and then spread them using a spreader.

[0127] (4) Slice and place in a 60℃ oven for 2 hours.

[0128] (5) Add anhydrous ethanol, 95% ethanol, xylene, and hematoxylin to the staining and mounting machine, and use the staining and mounting machine to stain the tissue sections to achieve the purpose of observing the tissue morphology under a microscope. Shake well on a shaker, add neutral resin glue to the staining and mounting machine, and mount the sections.

[0129] (6) Observe the tissue morphology under a microscope. After scanning with a slide scanner, observe the changes in follicles of various grades and ovarian stroma in the ovarian tissue, and count the primary follicles, secondary follicles, antral follicles and atretic follicles in each slide.

[0130] 2.10 Statistical Methods General data were analyzed using descriptive methods, and count data were described using proportions. Quantitative data underwent a normality test; if they conformed to a normal distribution, the mean ± standard deviation was used as the statistical unit. ) indicates that a distribution not satisfying a normal distribution is defined by the median and the upper and lower quartiles M(P). 25 ,P 75 )express.

[0131] When comparing data from multiple groups, one-way ANOVA analysis is used for data that conform to a normal distribution and have homogeneous variances, and LSD is used for post-hoc tests; Welch's ANOVA is used for data with heterogeneous variances, and Games-Howell is used for post-hoc tests; for data that do not conform to a normal distribution, nonparametric tests, such as the Kruskal-Wallis H test, are used, and Bonferroni correction is used for post-hoc tests.

[0132] Data were analyzed using SPSS 25.0 statistical software, with P < 0.05 considered statistically significant.

[0133] 3. Results Analysis 3.1 General condition and weight changes of rats During the acclimatization feeding phase, the rats exhibited normal activity and diet, and their fur remained smooth. No rat deaths occurred in any group during the experiment.

[0134] Changes in body weight during rat growth, as follows Figure 1 As shown, on day 1 (D1), there was no difference in body weight among the groups (P>0.05); after day 14, compared with other groups, the Model group rats had a faster rate of body weight gain; the Progynova group rats showed slight fluctuations in body weight from day 13 to day 29; on day 29, the Model group rats had the highest body weight and the Progynova group rats had the lowest body weight, but there was no significant difference in body weight among the groups (P>0.05).

[0135] 3.2 Rat ovarian index The ovarian indices of rats in each group followed a normal distribution with unequal variances. Welch's ANOVA was used, and Games-Howell post-hoc tests were performed. The results of the ovarian indices of rats in each group are shown below. Figure 2 As shown, the results indicated that the ovarian index of rats in the Model group was lower than that in the control group (P<0.05). Compared with the Model group, the ovarian index of mice in each dose group of JJGS and the Progynova group was increased. Among them, the ovarian index of Progynova and JJGS-M groups was significantly different from that of the Model group (P<0.001).

[0136] 3.3 Changes in the estrous cycle of rats Typical images of vaginal smears from rats during each estrous cycle are shown below. Figure 3 As shown, vaginal smears were taken from rats in groups D15-28 at 20:00 daily to monitor changes in the estrous cycle. The results are as follows. Figure 4 As shown in the figure. The results indicate that the estrous cycle in the Control group showed regular changes, while the estrous cycle in the Model group was disordered, with large fluctuations or stagnation in some cycles. The degree of estrous cycle disorder in the Progynova, JJGS-L, JJGS-M, and JJGS-H groups was less than that in the Model group.

[0137] 3.4 Serum sex hormone levels in rats Rat serum FSH and AMH did not follow a normal distribution, so nonparametric tests were used for analysis; E2 and LH followed a normal distribution, but the variances were unequal, so Welch's ANOVA was used, and Games-Howell post-hoc tests were used.

[0138] Table 8 shows that, compared with the Control group, the Model group had significantly different levels of FSH (P<0.01), AMH (P<0.05), and E2 (P<0.05). Specifically, FSH was elevated, while AMH and E2 were decreased, and LH levels were similar to those in the Control group. Compared with the Model group, drug intervention affected the levels of some sex hormones. The JJGS-M and JJGS-H groups significantly decreased FSH levels (P<0.05) and increased AMH levels (P<0.05). The Progynova, JJGS-L, JJGS-M, and JJGS-H groups all significantly increased E2 levels (P<0.01). The Progynova, JJGS-L, JJGS-M, and JJGS-H groups showed higher LH levels than the Model group, but the differences were not statistically significant (P>0.05).

[0139] Table 8. Serum sex hormone levels in rats Note: Compared to the Control group, ## P<0.01, # P<0.05; compared with the Model group, ** P<0.01, * P<0.05 3.5 HE staining and follicle counting of rat ovarian tissue The rat ovarian tissue was stained with hematoxylin and eosin (HE) to evaluate the pathological results, as shown in the following figures. Figure 5 As shown, the ovarian tissue structure of each group was clear and the cross-sectional size was basically similar. Compared with the Control group, the Model group had fewer follicles at each stage and more atretic follicles. Compared with the Model group, the JJGS-M and JJGS-H groups had more mature follicles, while the JJGS-L and Progynova groups had more follicles. All groups showed more large vacuoles than the Model group.

[0140] The number of primary follicles, secondary follicles, mature follicles, and corpora lutea did not conform to a normal distribution, so nonparametric tests were used for analysis. The number of primordial follicles and atretic follicles conformed to a normal distribution, but the variances were unequal, so Welch's ANOVA was used, and Games-Howell was used for post-hoc tests.

[0141] according to Figure 6The results showed that the number of primordial follicles, primary follicles, and corpora lutea in the Model group was lower than that in the Control group, but the difference was not statistically significant (P>0.05); the number of secondary follicles and mature follicles in the Model group was significantly lower than that in the Control group (P<0.01). After drug intervention, the number of mature follicles in the JJGS-M and JJGS-H groups was significantly higher than that in the Model group (P<0.01); the number of atretic follicles in the Model group was higher than that in the Control group, and the difference was statistically significant (P<0.01), while the number of atretic follicles in the JJGS-M and JJGS-H groups was significantly lower than that in the Model group (P<0.05).

[0142] The follicular atresia rate of each group was calculated. The values ​​conformed to a normal distribution and had homogeneous variances. One-way ANOVA analysis was used.

[0143] according to Figure 7 The results showed that the follicular atresia rate in the Model group was significantly higher than that in the Control group (P<0.001). After drug intervention, the follicular atresia rates in the JJGS-L and JJGS-M groups were significantly improved compared with those in the Model group (P<0.001), the follicular atresia rate in the Progynova group was improved compared with those in the Model group (P<0.01), and the follicular atresia rate in the JJGS-H group was significantly improved compared with those in the Model group (P<0.05).

[0144] The preferred embodiments of the present invention have been described in detail above. However, the present invention is not limited to the specific details in the above embodiments. Within the scope of the technical concept of the present invention, various simple modifications can be made to the technical solution of the present invention, and these simple modifications all fall within the protection scope of the present invention.

[0145] It should also be noted that the various specific technical features described in the above specific embodiments can be combined in any suitable manner without contradiction. In order to avoid unnecessary repetition, the present invention will not describe the various possible combinations separately.

Claims

1. A traditional Chinese medicine composition for improving ovarian function, characterized in that, Based on the weight percentages, it comprises the following raw materials: ginseng 1-5 parts, dodder seed 8-20 parts, angelica 3-14 parts, salvia miltiorrhiza 8-20 parts, morinda officinalis 4-14 parts, prepared rehmannia root 6-15 parts, wolfberry 6-14 parts, privet fruit 6-18 parts, cornus officinalis 3-13 parts, cyperus rotundus 3-13 parts, epimedium 3-12 parts, and licorice 1-10 parts.

2. The traditional Chinese medicine composition according to claim 1, characterized in that, The traditional Chinese medicine composition comprises, by weight, the following raw materials: ginseng 1-4 parts, dodder seed 9-17 parts, angelica 4-12 parts, salvia miltiorrhiza 9-17 parts, morinda root 5-13 parts, prepared rehmannia root 8-13 parts, wolfberry 7-13 parts, privet fruit 7-16 parts, cornus officinalis 4-12 parts, cyperus rhizome 4-12 parts, epimedium 5-11 parts, and licorice root 1-8 parts.

3. The traditional Chinese medicine composition according to claim 1 or 2, characterized in that, The traditional Chinese medicine composition, by weight parts The ingredients include the following raw materials: ginseng 3 parts, dodder seed 12 parts, angelica 6 parts, salvia miltiorrhiza 12 parts, morinda root 9 parts, prepared rehmannia root 9 parts, wolfberry 9 parts, privet fruit 9 parts, cornus officinalis 6 parts, cyperus rhizome 6 parts, epimedium 9 parts, and licorice root 6 parts. Preferably, the traditional Chinese medicine composition comprises, by weight, the following raw materials: 3 parts ginseng, 15 parts dodder seed, 10 parts angelica, 15 parts salvia miltiorrhiza, 12 parts morinda officinalis, 12 parts prepared rehmannia root, 12 parts wolfberry, 15 parts privet fruit, 10 parts cornus officinalis, 10 parts cyperus rotundus, 9 parts epimedium and 6 parts licorice. Preferably, the traditional Chinese medicine composition comprises, by weight, the following raw materials: 2 parts ginseng, 10 parts dodder seed, 8 parts angelica, 10 parts salvia miltiorrhiza, 6 parts morinda officinalis, 9 parts prepared rehmannia root, 9 parts wolfberry, 9 parts privet fruit, 6 parts cornus officinalis, 6 parts cyperus rotundus, 6 parts epimedium and 2 parts licorice.

4. The traditional Chinese medicine composition according to claim 1 or 2, characterized in that, The Morinda officinalis mentioned is processed Morinda officinalis; Preferably, the privet fruit is *Ligustrum lucidum*, also known as wine privet fruit; Preferably, the Cornus officinalis is the fleshy part of Cornus officinalis used in wine making; Preferably, the licorice is roasted licorice.

5. A method for preparing the traditional Chinese medicine composition as described in claim 1, characterized in that, The preparation method includes: weighing ginseng, dodder seed, angelica, salvia miltiorrhiza, morinda officinalis, rehmannia glutinosa, wolfberry, privet fruit, cornus officinalis, cyperus rotundus, epimedium and licorice according to the selected mass proportions, mixing them and then extracting them to obtain the final product.

6. The preparation method according to claim 5, characterized in that, The extraction method includes one or more of the following: decoction extraction, maceration extraction, percolation extraction, reflux extraction, and ultrasonic extraction, especially decoction extraction; Preferably, the extraction is performed at least once, more preferably 1-5 times, and even more preferably 1-3 times; Preferably, the extraction time is at least 20 min, more preferably 20-120 min, and even more preferably 20-90 min.

7. A traditional Chinese medicine preparation for improving ovarian function, characterized in that, The active ingredients in the traditional Chinese medicine preparation include the traditional Chinese medicine composition as described in any one of claims 1-4 or the traditional Chinese medicine composition obtained by the preparation method described in claim 5.

8. The traditional Chinese medicine preparation according to claim 7, characterized in that, The traditional Chinese medicine preparations include decoctions, pills, capsules, granules, tablets, pastes, drop pills, plasters, or lotions, with decoctions being the preferred form. Preferably, the traditional Chinese medicine preparation further includes pharmaceutically acceptable excipients selected from one or more of the following: solubilizers, cosolvents, emulsifiers, colorants, binders, disintegrants, fillers, lubricants, wetting agents, osmotic pressure regulators, stabilizers, flow aids, flavoring agents, preservatives, suspending agents, coating materials, fragrances, anti-adhesives, integrators, penetration enhancers, pH adjusters, buffers, plasticizers, surfactants, thickeners, inclusion agents, humectants, absorbents, diluents, flocculants and anti-flocculators, filter aids, release inhibitors, polymeric framework materials, and film-forming materials.

9. A method for preparing a traditional Chinese medicine preparation as described in claim 7, characterized in that, The preparation method includes the following steps: 1) Extraction of Chinese herbal composition: Weigh out ginseng, dodder seed, angelica, salvia miltiorrhiza, morinda officinalis, rehmannia glutinosa, wolfberry, privet fruit, cornus officinalis, cyperus rotundus, epimedium and licorice according to the selected mass proportions, mix and extract, filter and concentrate to obtain the Chinese herbal composition extract. 2) Add excipients to the extract of the traditional Chinese medicine composition to prepare a dosage form that is acceptable in clinical practice.

10. The use of the traditional Chinese medicine composition as described in any one of claims 1-4, or the traditional Chinese medicine composition obtained by the preparation method described in claim 5, or the traditional Chinese medicine preparation as described in claim 7, or the traditional Chinese medicine preparation obtained by the preparation method described in claim 9, in the preparation of a drug for improving ovarian function; Preferably, diseases causing decreased ovarian function include premature ovarian insufficiency (POI), decreased ovarian reserve, ovarian hyporesponsiveness, perimenopausal syndrome, and secondary ovarian injury.

Citation Information

Patent Citations

  • A traditional Chinese medicine composition for treating premature ovarian failure and its preparation method

    CN101850016B

  • Traditional Chinese medicine composition as well as preparation method and application thereof

    CN101919963B